SCHEMBL25271978

SCHEMBL25271978

CCn1ncc2ccc(N)c(OC)c21

nearest known ligand 0.44

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HTR2C P28335 9/20 0.44
HTR2A P28223 8/20 0.44
HASPIN Q8TF76 1/20 0.43
ALDH1A1 P00352 3/20 0.39
HTT P42858 2/20 0.39
HSD17B10 Q99714 2/20 0.39
HTR2B P41595 6/20 0.37
NPC1 O15118 2/20 0.36
RAB9A P51151 2/20 0.36
KDM4E B2RXH2 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
HSP90AB1 P08238 1/20 0.35
HPGD P15428 1/20 0.35
CA12 O43570 1/20 0.34
CA1 P00915 1/20 0.34
CA2 P00918 1/20 0.34
CA9 Q16790 1/20 0.34
MAPK1 P28482 1/20 0.34
TLR7 Q9NYK1 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30498188 0.90 HASPIN (0.40) HTR2CHTR2AHASPINALDH1A1HTT
Hydrochloric Acid SCHEMBL25289529 0.87 HTR2A (0.41) HTR2CHTR2AALDH1A1HTTHSD17B10
SCHEMBL27199681 0.84 HSD17B10 (0.42) HTR2CHTR2AALDH1A1HTTHSD17B10
SCHEMBL30498325 0.84 HTR2A (0.41) HTR2CHTR2AALDH1A1HTTHSD17B10
SCHEMBL25753130 0.84 HTR2A (0.41) HTR2CHTR2AALDH1A1HTTHSD17B10
SCHEMBL31359665 0.82 HTR2A (0.40) HTR2CHTR2AALDH1A1HTTHSD17B10
SCHEMBL25753193 0.82 HTR2C (0.49) HTR2CHTR2AALDH1A1HTTHSD17B10
SCHEMBL25282158 0.82 HTR2A (0.40) HTR2CHTR2AALDH1A1HTTHSD17B10
SCHEMBL30498270 0.82 HTR2A (0.40) HTR2CHTR2AALDH1A1HTTHSD17B10
SCHEMBL25234617 0.81 HTR2A (0.38) HTR2CHTR2AHASPINALDH1A1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250115597-A1 TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF LYNK PHARMACEUTICALS CO LTD (CN) 2025-04-10 US disclosed
US-12129250-B2 TYK2 inhibitors and compositions and methods thereof LYNK PHARMACEUTICALS CO. LTD. (CN) 2024-10-29 US disclosed
EP-4448514-A1 TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF Lynk Pharmaceuticals Co. Ltd. (CN) 2024-10-23 EP disclosed
US-20240124448-A1 TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF LYNK PHARMACEUTICALS CO. LTD. (CN) 2024-04-18 US disclosed
WO-2023109954-A1 TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF LYNK PHARMACEUTICALS CO. LTD. (CN) 2023-06-22 WO disclosed
WO-2023109954-A1 TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF LYNK PHARMACEUTICALS CO. LTD. (CN) 2023-06-22 WO disclosed
WO-2023109120-A1 TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF LYNK PHARMACEUTICALS CO. LTD. (CN) 2023-06-22 WO disclosed
WO-2023109120-A1 TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF LYNK PHARMACEUTICALS CO. LTD. (CN) 2023-06-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240124448-A1 TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF TYK2, JAK2, JAK1 HTR2C 3809/4885HTR2A 3276/4885HASPIN 1549/4885
US-20250115597-A1 TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF TYK2, JAK2, JAK1 HTR2C 3809/4885HTR2A 3276/4885HASPIN 1549/4885
US-12129250-B2 TYK2 inhibitors and compositions and methods thereof TYK2, JAK2, JAK1 HTR2C 3809/4885HTR2A 3276/4885HASPIN 1549/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.